Adverum Biotechnologies appoints Dr. Reed Tuckson to its Board as Independent Director

– USA, CA –  Adverum Biotechnologies, Inc. (NASDAQ: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dr. Reed Tuckson, M.D., FACP to its Board as an Independent Director.

Dr. Tuckson brings extensive policy knowledge from his experience in multiple facets of the healthcare industry, including a 13-year tenure in senior leadership positions at UnitedHealth Group, where he served as chief of medical affairs.

“Reed’s leadership and deep healthcare policy expertise, from clinical services administration and medical policies to consumer health engagement, will be a tremendous asset to Adverum as we prepare for global commercialization of ADVM-022, the first mass market gene therapy product for the treatment of patients with wet AMD and DME,” said CEO, Dr. Laurent Fischer. “During his career, Reed has exhibited a commitment to putting patients first while enhancing quality and efficiency in care delivery as exemplified by his recent involvement in improving access to COVID-19 vaccines in disproportionally impacted minority populations. With Reed and the recent appointment of Dawn Svoronos, we have strengthened our breadth of leadership in commercialization and healthcare policy at the director level. Additionally, we are committed to leading our industry with a highly diverse and qualified board. We extend a warm welcome to Reed.”

About Dr. Reed Tuckson

Since 2013, Dr. Reed Tuckson has held the position of managing director of Tuckson Health Connections, a private consulting company. Previously, he served as EVP and chief of medical affairs, as well as SVP, clinical affairs, for UnitedHealth Group, where he oversaw the medical and clinical-related policies and activities.

Dr. Tuckson has also held positions as SVP for professional standards of the American Medical Association; president of the Charles R. Drew University of Medicine and Science in Los Angeles, California; SVP for programs of the March of Dimes Birth Defects Foundation; and Commissioner of Public Health for the District of Columbia.

A recognized leader in his field, Dr. Tuckson serves on the board of directors of CTI BioPharma Corp., Alliance for Health Policy, and Project Sunshine. Additionally, he is a member of the advisory board of the National Institutes of Health Clinical Center and serves on several committees of the National Academy of Medicine.

“This is an incredibly exciting time to join Adverum as a director,” said Dr. Tuckson. “ADVM-022 has the potential to dramatically reduce the treatment and societal burden for millions of patients worldwide living with wet AMD and DME, two leading causes of blindness. This is particularly important in minority and underserved communities where the frequency of current standard-of-care treatment can create barriers to access that can lead to unintended vision loss. I am honored to play a role in Adverum’s continued development of ADVM-022 and look forward to bringing a fully encompassing approach to patient health and well-being in support of the company’s mission to preserve patient sight for life.”

Dr. Tuckson received a B.S. from Howard University and an M.D. from Georgetown University School of Medicine. He completed the University of Pennsylvania Hospital’s General Internal Medicine Residency and Fellowship programs.

About Adverum Biotechnologies

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team